VR Adviser’s ARS Pharmaceuticals SPRY Stock Holding History

VR Adviser’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-85,000	Closed	-$3.71M	–	32
2021 Q1	$3.71M	Sell	85,000 -65,000	-43%	-$3.08M	0.4%	26
2020 Q4	$6.95M	Buy	+150,000	New	+$5.01M	1.02%	19

Other funds holding SPRY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

VR Adviser's SPRY Position: Q2 2021 in Review

VR Adviser sold out of ARS Pharmaceuticals (SPRY) in Q2 2021, closing a stake of 85,000 shares — an estimated $3.71M sold.

VR Adviser first reported a position in SPRY in Q4 2020 and held it in 2 quarters. The position peaked at $6.95M in Q4 2020. 76 funds tracked by Wall St. Rank hold SPRY as of Q2 2021.

VR Adviser reported no remaining ARS Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
VR Adviser sold 85,000 ARS Pharmaceuticals shares in Q2 2021, an estimated $3.71M.
VR Adviser first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 2 quarters.
VR Adviser's ARS Pharmaceuticals position peaked at $6.95M in Q4 2020.
76 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2021.

Based on VR Adviser's 13F filing for Q2 2021, filed 13 Aug 2021.